The Axikin discovery biology and portfolio of small molecules focuses on novel GPCR and kinase targets central to the inflammatory process, the antagonism of which is predicted to ameliorate allergic respiratory disorders such as rhinitis and asthma, in addition to significantly impacting the inflammation observed in COPD.
Axikin was created as a spin-off from Actimis Pharmaceuticals, Inc., following the structured acquisition of Actimis by Boehringer Ingelheim. Actimis was originally spun out of the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG.
With a rapidly growing portfolio of highly-optimized small molecules, Axikin is well-poised to draw upon significant in-house expertise in anti-inflammatory drug development to move its lead GPCR program towards an IND within an accelerated timeframe. In addition, Axikin has entered into strategic collaborations that will enable target validation, small molecule screening and lead optimization for it’s kinase program.
Axikin has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York, and retains the same Management and scientific teams from the Actimis organization.